Who discovered Angelman syndrome?
Angelman syndrome was first described in the medical literature in 1965 by Dr. Harry Angelman, an English physician. The characteristic findings of Angelman syndrome are not usually apparent at birth and diagnosis of the disorder is usually made between 1 and 4 years of age.
How does Angelman syndrome affect the nervous system?
Angelman syndrome is a rare and complex neurodevelopmental condition that causes developmental delays, intellectual disabilities, speech impairments and movement issues. It’s caused by issues with a specific gene called UBE3A that happens during fetal development.
What type of mutation causes Angelman syndrome?
Angelman syndrome is a genetic disorder. It’s usually caused by problems with a gene located on chromosome 15 called the ubiquitin protein ligase E3A (UBE3A) gene.
How does genomic imprinting cause Angelman syndrome?
The syndrome results from deletion or mutation within maternal chromosome 15q11-q13. Considerable evidence suggests that the gene or genes responsible for Angelman syndrome are expressed only from the maternal chromosome 15, a situation known as parental imprinting.
What is the genotype for Angelman syndrome?
Angelman syndrome (AS) is a rare neurodevelopmental disease that is caused by the loss of function of the maternal copy of ubiquitin–protein ligase E3A (UBE3A) on the chromosome 15q11–13 region.
What part of the brain does Angelman syndrome affect?
Molecular pathogenesis: The contribution of the hippocampus, cortex, and cerebellum
| Brain area | Model |
|---|---|
| Hippocampus and cortex | AS mice and human samples |
| Hippocampus and cerebellum | AS mice |
| Hippocampus, cortex, and cerebellum | AS mice |
| Cortex | AS mice |
What is imprinting in Angelman syndrome?
Genomic imprinting and Angelman syndrome. Genomic imprinting refers to a process whereby the maternal copy of a gene can be marked or “imprinted” differently than the paternal copy of the same gene (Reik and Walter, 2001).